GenSight Biologics seeks EU approval for gene therapy
Lumevoq is designed to treat vision loss associated with Leber Hereditary Optic Neuropathy
Read More
Tag: GenSight Biologics
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
